Portfolio company
Attovia Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
The company develops biparatopic biologics to treat patients with immune-mediated diseases and cancer through a modular protein design platform.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ATB Therapeutics
The company develops engineered antibody therapies for patients with cancer and autoimmune diseases using a proprietary bioengineering platform.
EpiBiologics
This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.
Boulevard Bio
This clinical-stage biotechnology company develops multi-specific antibody therapies for patients suffering from B cell-driven autoimmune diseases.
Epana Bio
This company develops precision T-cell engagers and biologics using artificial intelligence and genomics to treat patients with autoimmune diseases.
Lycia Therapeutics
The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.
HI-Bio
This biotechnology company develops targeted therapies for patients suffering from severe immune-mediated diseases.
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Nuvig
Nuvig Therapeutics develops immunomodulatory medicines to treat patients with chronic inflammatory and autoimmune diseases.